Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Citius Oncology, Inc.NASDAQ: CTOR
Other Current Liabilities · Q2 FY2026 · quarter ended Mar 2026
Other current liabilities falls 8.9% from a year ago
Other current liabilities stood at $25.87M at the end of Q2 FY2026, down 8.9% from a year earlier and up 41.8% from the prior quarter.
Context
- Other current liabilities amounted to 25.7% of total assets at the end of Q2 FY2026, down 5.4 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -8.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.65M USD
- Year-over-year change
- -20.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 22.65M | -20.2% |
| FY2024 | 2024-09-30 | 28.4M | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Other Current Liabilities vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 other current liabilities of $25.87M is the 2nd highest of the 10 companies compared; the peer median is $3.52M.
- Its year-over-year change of -8.9% is the 5th highest of 9, against a peer median of +3.3%.
- Other current liabilities amounts to 25.7% of total assets for CTOR, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $308.06M | +70394.3% | +945.6% | 104.9% | |
CTORCitius Oncology, Inc. | Mar 2026 | $25.87M | -8.9% | — | 25.7% |
| Mar 2026 | $12.89M | — | — | 14.9% | |
| Mar 2026 | $8.45M | -29.8% | -40.5% | 3.0% | |
| Mar 2026 | $4.3M | +63.4% | -49.2% | 3.7% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $3.52M | +184.4% | +20.0% | 39.5% |
| Mar 2026 | $2.92M | +36.3% | +45.8% | 0.6% | |
| Mar 2026 | $1.64M | -87.1% | +62.3% | 2.5% | |
| Mar 2026 | $878K | -29.8% | +36.2% | 1.3% | |
| Mar 2026 | $0 | -100.0% | -7.4% | 0.0% | |
| Peer median (excluding CTOR) | $3.52M | +3.3% | +28.1% | 3.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.